Your browser doesn't support javascript.
loading
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul, Dimpy; Wang, Shuzhen; Wu, Shaofang; Saito, Norihiko; Zheng, Siyuan; Gao, Feng; Kaul, Isha; Setoguchi, Masaki; Nakayama, Kiyoshi; Koyama, Kumiko; Shiose, Yoshinobu; Sulman, Erik P; Hirota, Yasuhide; Yung, W K Alfred.
Afiliación
  • Koul D; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang S; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wu S; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Saito N; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Zheng S; Brain Tumor Center, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gao F; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kaul I; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Setoguchi M; Medicinal Chemistry Research Laboratories, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
  • Nakayama K; Medicinal Chemistry Research Laboratories, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
  • Koyama K; Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
  • Shiose Y; Oncology Research Laboratories, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
  • Sulman EP; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hirota Y; Oncology Research Laboratories, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
  • Yung WKA; Brain Tumor Center, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncotarget ; 8(13): 21741-21753, 2017 Mar 28.
Article en En | MEDLINE | ID: mdl-28423515
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Neoplasias Encefálicas / Adenina / Fosfohidrolasa PTEN / Inhibidores de las Quinasa Fosfoinosítidos-3 / Glioma / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperazinas / Neoplasias Encefálicas / Adenina / Fosfohidrolasa PTEN / Inhibidores de las Quinasa Fosfoinosítidos-3 / Glioma / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos